Buscar
Theriva Biologics Inc
TOVXAñadir a la lista de seguimiento
0.211USD
+0.001+0.48%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
9.69MCap. mercado
PérdidaP/E TTM
Más Datos de Theriva Biologics Inc Compañía
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Información de Theriva Biologics Inc
Símbolo de cotizaciónTOVX
Nombre de la empresaTheriva Biologics Inc
Fecha de salida a bolsaFeb 12, 1993
Director ejecutivoShallcross (Steven A)
Número de empleados22
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 12
Dirección9605 Medical Center Drive, Suite 270
CiudadROCKVILLE
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísUnited States of America
Código postal20850
Teléfono17343327800
Sitio Webhttps://therivabio.com/
Símbolo de cotizaciónTOVX
Fecha de salida a bolsaFeb 12, 1993
Director ejecutivoShallcross (Steven A)
Ejecutivos de Theriva Biologics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Steven A. (Steve) Shallcross
Mr. Steven A. (Steve) Shallcross
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
10.00K
-287.04%
Mr. Jeffrey J. (Jeff) Kraws
Mr. Jeffrey J. (Jeff) Kraws
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Independent Director
Independent Director
--
--
Dr. John Monahan, Ph.D.
Dr. John Monahan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Chris Calabrese
Mr. Chris Calabrese
IR Contact Officer
IR Contact Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Steven A. (Steve) Shallcross
Mr. Steven A. (Steve) Shallcross
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
10.00K
-287.04%
Mr. Jeffrey J. (Jeff) Kraws
Mr. Jeffrey J. (Jeff) Kraws
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Independent Director
Independent Director
--
--
Dr. John Monahan, Ph.D.
Dr. John Monahan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Chris Calabrese
Mr. Chris Calabrese
IR Contact Officer
IR Contact Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Theriva Biologics Inc?
Los cinco principales accionistas de Theriva Biologics Inc son: Mr. Steven A. (Steve) Shallcross
¿Cuántas instituciones poseen acciones de Theriva Biologics Inc (TOVX)?
A fecha de 2026Q1, 51 instituciones poseen acciones de Theriva Biologics Inc, con un valor de mercado combinado de aproximadamente 1.78M, lo que representa el 3.88% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 332025.00.